MARTINEZ ROMAN IV

SEC source: 0001225208-20-014152 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,839

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020.

SEC source: 0001225208-20-011220 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,612

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020.

SEC source: 0001225208-20-008486 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,345

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020.

SEC source: 0001225208-20-004182 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,105

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-015090 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,846

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-012166 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,609

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-008810 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,301

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-004404 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,981

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001567619-18-008649 · doc1.xml · derivative · entry 2

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $.25 Par Value · 15,426 shares

Expires not disclosed

F3 · security: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · kind: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.expiration_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

SEC source: 0001567619-18-008649 · doc1.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008707 · doc1.xml · derivative · entry 2

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,426

Underlying: Common Stock, $0.01 Par Value · 15,426 shares

Expires not disclosed

F3 · security: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · kind: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.expiration_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

SEC source: 0001567619-18-008707 · doc1.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,709

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001225208-18-016221 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,709

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001225208-18-013183 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,508

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001104659-18-038962 · a4.xml · derivative · entry 4

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,633 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger.

F3 · price: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger.

SEC source: 0001104659-18-038962 · a4.xml · derivative · entry 3

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,566 shares

Expires not disclosed

F2 · derivative.exercise_price: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger.

F2 · price: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger.

SEC source: 0001104659-18-038962 · a4.xml · nonDerivative · entry 2

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of September 17, 2017 (the "Merger Agreement"), among Northrop Grumman Innovation Systems, Inc. (formerly known as Orbital ATK, Inc.) (the "Company"), Northrop Grumman Corporation and Neptune Merger, Inc., a wholly owned subsidiary of Northrop Grumman Corporation ("Sub"), effective as of immediately prior to the effective time of the merger of the Company and Sub (the "Merger"), these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $134.50.

SEC source: 0001104659-18-038962 · a4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of September 17, 2017 (the "Merger Agreement"), among Northrop Grumman Innovation Systems, Inc. (formerly known as Orbital ATK, Inc.) (the "Company"), Northrop Grumman Corporation and Neptune Merger, Inc., a wholly owned subsidiary of Northrop Grumman Corporation ("Sub"), effective as of immediately prior to the effective time of the merger of the Company and Sub (the "Merger"), these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $134.50.

SEC source: 0001225208-18-010122 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,270

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001140361-18-024355 · doc1.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,633

Underlying: Common Stock · 18.2836 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

SEC source: 0001140361-18-014142 · doc1.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,615

Underlying: Common Stock · 18.4079 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

SEC source: 0001225208-18-005160 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,005

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's preliminary proxy statement filed with the SEC on March 2, 2018.

SEC source: 0001140361-17-044802 · doc1.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,597

Underlying: Common Stock · 18.3801 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

SEC source: 0001225208-17-018126 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,776

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001140361-17-036308 · doc1.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,578

Underlying: Common Stock · 18.2734 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

SEC source: 0001225208-17-014581 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,564

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001140361-17-032167 · doc1.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,566

Underlying: Common Stock · 1,133 shares

Expires not disclosed

F1 · security: The reporting person has elected to defer the receipt of 1,133 shares of common stock granted pursuant to the Non-Employee Director Stock Program under the Issuer's 2015 Stock Incentive Plan.

F2 · derivative.exercise_price: Converts to common stock 1-for-1.

F1 · price: The reporting person has elected to defer the receipt of 1,133 shares of common stock granted pursuant to the Non-Employee Director Stock Program under the Issuer's 2015 Stock Incentive Plan.

F3 · derivative.exercise_date: The deferred stock units are to be settled 100% in common stock as soon as practicable after the reporting person ceases to be a director of the Issuer.

F3 · derivative.expiration_date: The deferred stock units are to be settled 100% in common stock as soon as practicable after the reporting person ceases to be a director of the Issuer.

SEC source: 0001140361-17-025873 · doc1.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,560

Underlying: Common Stock · 23.9242 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

SEC source: 0001225208-17-010846 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,317

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001104659-17-019180 · a4.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,536

Underlying: Common Stock · 24.3003 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

SEC source: 0001225208-17-005389 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,038

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016.

SEC source: 0001104659-16-159996 · a4.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,512

Underlying: Common Stock · 26.3173 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

SEC source: 0001225208-16-042626 · doc4.xml · nonDerivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,736

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016.

SEC source: 0001104659-16-146173 · a4.xml · derivative · entry 1

MARTINEZ ROMAN IV · CIK 0001276303 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,486

Underlying: Common Stock · 30.2201 shares

Expires not disclosed

F1 · security: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F2 · derivative.exercise_price: 1-for-1.

F1 · derivative.exercise_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.

F1 · derivative.expiration_date: These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer.